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dipivoxil therapy in chronic hepatitis B patients
with poor response to adefovir dipivoxil
monotherapy
E.-Q. Chen1 *, T.-Y. Zhou1, H. Tang1. 1Center of Infectious
Diseases, West China Hospital of Sichuan University,
Chengdu, Sichuan 610041, People’s Republic of China
Objectives: At present, there is no consensus of telbivudine
(LdT) treatment for chronic hepatitis B (CHB) patients who
have poor response to adevoﬁr dipivoxil (ADV) monotherapy.
The aim of this study was to assess the therapeutic
effectiveness of LdT, administered in combination with ADV
in CHB patients with poor response to ADV monotherapy.
Methods: Twenty-four adult outpatients aged >18 years
with HBVDNA 103 copies/mL and normal alanine
aminotransferase (ALT) after at least 48 weeks of ADV initial
monotherapy were included and immediately received ADV
plus LdT combination treatment in this prospective study.
HBVDNA and ALT levels were checked every 3 month. The
proportions of patients who achieved virologic response (VR,
undetectable HBV-DNA [<103 copies/mL]) were analyzed,
and serum creatine kinase (CK) and creatinine (Cr) after
combination therapy were observed.
Results: At baseline of combination treatment, the mean
level of HBVDNA was 4.05 log (10) copies/mL. Compared
with baseline, the mean decrease in HBVDNA level at
week 12 and 24 were 0.89 log10 and 1.31 log10 copies/mL,
respectively, and the decreasing was signiﬁcant (p < 0.001for
week 12, and p < 0.001 for week 24). The VR rate was
41.7% and 66.7% at weeks 12 and 24, respectively, and the
difference in VR between week 12 and 24 was signiﬁcant
(p = 0.003). During the initial 24 weeks combination therapy,
no elevated ALT, CK, and Cr were detected.
Conclusions: Adding LdT may be a good choice for CHB
patients with poor response to ADV monotherapy. And
further long-term study was necessary to conﬁrm the
results.
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Background: HBsAg seropositivity rate in healthy Mongolian
population is about 10%. Although the prevalence for the
virus infection has been conﬁrmed in many other studies,
the extended investigation for other viral markers was not
reported before.
Method: Total of 1,961 patients were assessed for ﬁve
HBV seromarkers HBsAg, HBeAb, HBsAb, and HBeAb, YBcAb
during January 2009 and October 2009. HBV combo test
was purchased from ACON Laboratories, Inc, USA. CBC was
done using Sysmex, XS800i hematology analyzer, Japan,
Statistical analysis was performed Microsoft Excel software.
Out of 1,961 patients 381 were positive for HBsAg.
Result: In this single center study, we analyzed all patients
(n = 381) positive for HBsAg. HBV infected males represented
53.2% (n = 203) of the total, with females representing
46.8% (n = 178). Only 3.6% of HBsAg positive patients were
positive for HBeAg, with equal sex proportions. HBeAb+
patients comprise 19.9% (n = 76), out of which 77.6% (n+59)
were positive for both HBcAb and HBeAb. Patients with
HBcAb comprise 39.3% (n = 150) of the pool, with males
representing 59.4% (n = 89). 203 patients (53.2%) were only
positive for HBsAg, with no any antibodies present. We
also checked platelet numbers for clues of liver cirrhosis.
According to our study 8.8% (n = 8) of the patients who had
full CBC (n = 90) were cirrhotic. All of those patients had
albumin level <3.4 g/dL. Patient with double infection for
both HCV (anti-HCV) and HBV (HBsAg) made 3.6% (n = 14) of
the pool.
Conclusion: Cirrhotic patients may comprise nearly 9% of
HBV infected patients, which will make around 24,000
patients (0.8% of the country population). Patients with
bearing both HBV and HCV have higher risk of developing
liver cirrhosis 7.1% vs. 1.9% consistent with the data of
other countries. HBeAg positivity rate was very low 3.7%,
which is much lower than of western nations.
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Objectives: The purpose of this study was to develop a
quantitative analysis method for detecting the ratio of
HBV mutant/wild strains, which is standardized, direct and
precise.
Methods: We designed a sequence map analysis software
could calculate the relative proportions of mutant and
wild strains. Bi-directional sequencing was used to improve
the accuracy. Totally 62 Sera samples were collected
from patients with hepatitis B who were predicted to
develop viral breakthrough during lamivudine treatment at
infectious department of NanFang Hospital, between 2008
and 2009. For samples with YMDD mutantion detected by
PCR restriction-fragment-length-polymorphism (PCR-RFLP)
assay ﬁrstly, we sequenced them bi-directional. After
analysed the sequence maps by Chromas and DNAMAN and
picked out the maps with double peaks at YMDD sites, we
calculated the ratio of HBV mutant/wild strains.
Results: YMDD mutations were detected in 54 cases (54/62)
by PCR-RFLP assay. The results of Bi-directional sequencing:
22 cases were YMDD mutation completely while 32 cases
were found to coexist with wild-type virus. Among these
cases, YVDD/YMDD, YIDD/YMDD and L180M mutation coexist
with wild-type virus were 8, 6 and 27 cases, respectively.
YVDD/YMDD or YIDD/YMDD accompanied by L180M mutation
were 14 cases. Of all mixed infections cases, the smallest
ratio of mutant strain is 5.68%, and the maximum ratio is
93.82%.
Conclusions: We developed a quantitative analysis method
for detecting the ratio of HBV mutant/wild strains, which
is standardized, direct and precise. For further study, it
could be used to detect resistance of other nucleotides
(acid) analogues dynamically. Also we could use this
method to monitor a wide range of drug resistance loci
simultaneously, and ﬁnd new meaningful joint resistance
mutation. This method could provide information to make
a more reasonable prevention, diagnosis and treatment of
HBV infection.
